PUBLISHER: DataM Intelligence | PRODUCT CODE: 1588567
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1588567
Overview
The global longevity therapeutics market reached US$ 31.67 billion in 2023 and is expected to reach US$ 52.03 billion by 2031 growing with a CAGR of 6.4% during the forecast period 2024-2031.
Longevity therapeutics, also known as longevity medicine or anti-aging medicine, is a rapidly growing field that focuses on helping people live longer, and lead healthier lives. It employs a multifaceted approach that integrates diverse strategies to address the fundamental processes of aging.
The longevity therapeutics approach encompasses targeted drug therapies, gene-based interventions, regenerative medicine techniques, nutritional supplements, and lifestyle modifications, all of which are aimed at mitigating the detrimental effects of aging and promoting healthy longevity. The market includes various therapeutic categories, including pharmacological treatments, gene therapies, cell therapies, and lifestyle changes, all aimed at addressing different facets of the aging process.
Market Dynamics: Drivers
Rising prevalence of chronic diseases and the aging population
The demand for the global longevity therapeutics market is driven by multiple factors. The increasing prevalence of chronic diseases linked to aging, including cardiovascular diseases, neurodegenerative disorders, cancer, and metabolic disorders, is a major factor propelling the growth of the longevity therapeutics market. As the global population continues to age, the occurrence of these age-related conditions rises.
As per WHO data in October 2022, the increase in the number of individuals aged 65 and older, which is expected to double by 2050 to around 1.5 billion, the rising number of aging population and age-related diseases that would propel will the demand for the longevity therapeutics market. The growing awareness among the aging population regarding the significance of preventive healthcare will drive the demand for supplements, medications, and lifestyle changes designed to enhance longevity and avert age-related illnesses.
Moreover, key players in the industry research activities and developing awareness among individuals, are driving longevity therapeutics market growth. For instance, in February 2024, The Potocsnak Longevity Institute at Northwestern University Feinberg School of Medicine launched the Human Longevity Laboratory, an important longitudinal and cross-sectional study aimed at examining the connection between chronological age (the actual number of years a person has lived) and biological age. This research seeks to understand how these two forms of aging relate to one another across various organ systems and aims to validate interventions that could potentially slow down or reverse the aging process.
Also, in Longevity Technology news in September 2024, combination biologics are emerging as a promising strategy for longevity therapy, particularly in age-related diseases. This approach involves using multiple biological agents that target different pathways simultaneously, potentially enhancing therapeutic efficacy and addressing the complex nature of aging.
Similarly, in February 2024, ADvantage Therapeutics announced the appointment of Professor Makoto Kuro-o to its Scientific Advisory Board, recognizing his advanced contributions to aging research, particularly for discovering the Klotho gene associated with longevity and health in aging. This strategic addition aims to enhance the company's focus on developing therapies for neurodegenerative diseases.
Restraints
Factors such as regulatory challenges, ethical considerations, and limited clinical evidence, are expected to hamper the market.
The global longevity therapeutics market is segmented based on product type, application, distribution channels, and region.
The dietary supplements segment accounted for approximately 76.3% of the global longevity therapeutics market share
The dietary supplements segment is expected to hold the largest market share over the forecast period. This segment includes a variety of formulations designed to promote health and longevity. This segment primarily features two categories: nutraceuticals and vitamins and minerals, both of which play crucial roles in enhancing overall health and preventing age-related diseases.
Nutraceuticals, natural compounds extracted from food sources, are crucial players in the longevity therapeutics market. These substances offer health advantages beyond basic nutrition, making them increasingly attractive to consumers who want to extend their health span and reduce the risk of age-related illnesses. Resveratrol, nicotinamide mononucleotide (NMN), and coenzyme Q10 (CoQ10) are key examples of these nutraceuticals.
Nicotinamide mononucleotide (NMN) plays a pivotal role in the longevity market as a supplement aimed at enhancing health and mitigating age-related decline. NMN is a precursor to nicotinamide adenine dinucleotide (NAD+), a crucial molecule involved in energy metabolism, DNA repair, and various cellular processes. As individuals age, NAD+ levels naturally decline, which can negatively affect cellular function and contribute to the onset of age-related conditions such as neurodegenerative diseases, metabolic disorders, and decreased energy levels.
Moreover, key players in the industry launching innovative products that would drive this segment's growth in the longevity therapeutics market. For instance, Decode Age introduced the MAG7, (Seven Complex Magnesium), and Coenzyme Q10 (Ubiquinol).
Decode Age, a pioneering health and wellness brand in India, has launched "Decode Blood Age," the country's first blood-based biological age test. This innovative approach aims to provide individuals with insights into their true health status by analyzing specific biomarkers derived from blood samples. Unlike chronological age, which simply reflects the number of years a person has lived, biological age reveals the rate at which an individual's body is aging on a cellular level.
Also, Zeropharm introduced clinically validated NMN 250 MG + Berberine Capsules, each containing 250 mg of high-purity NMN and powerful Berberine. These capsules are formulated to enhance NAD+ levels, boost energy, improve focus, support cellular health, promote heart health, and contribute to long-term longevity. For optimal results, take one capsule daily after your morning meal. Experience increased vitality and overall well-being.
Similarly, TeloX is an innovative, plant-derived supplement that combines a potent blend of therapeutic polyphenols naturally extracted from olive leaf, grapevine, and Superoxide Dismutase (SOD). These phytochemical compounds possess powerful antioxidant properties that neutralize harmful free radicals and provide essential nutrients to support mitochondrial function and promote cellular longevity.
North America accounted for approximately 43.6% of the global longevity therapeutics market share
North America region is expected to hold the largest market share over the forecast period owing to the rising geriatric population and age-related diseases that would drive this market growth. Moreover, growing health consciousness, developments in biomedical research, and increased investment in longevity research and technological advancements would increase longevity therapeutics market growth in this region.
In addition, a major number of key players' presence, strategies such as partnerships & collaborations, and key developments would drive longevity therapeutics market growth. For instance, in April 2024, researchers at the Children's Hospital of Philadelphia (CHOP) and Stanford Medicine identified the FOXO1 protein as a critical factor in enhancing the longevity and effectiveness of CAR-T cells, which are engineered immune cells used in cancer treatment. This discovery is significant because the success of CAR-T cell therapy hinges on the ability of these cells to survive long enough in the body to effectively combat cancer.
Similarly, in California, in June 2024, Alamar Biosciences, a company focused on precision proteomics for early disease detection, announced the launch of the next phase of the Biomarkers of Aging Challenge Series in collaboration with the Biomarkers of Aging Consortium. This initiative aims to tackle one of the most pressing issues in the field of longevity, the need for reliable biomarkers that accurately reflect biological age.
The major global players in the longevity therapeutics market include Decode Age, Zeroharm, Gataca, Longevity By Nature, ProHealth, Inc., Xandro Lab., NanoSPACE, AgeX Therapeutics, Inc., T.A. SCIENCES, and Elysium Health, Inc. among others.
The global longevity therapeutics market report would provide approximately 62 tables, 52 figures, and 183 pages.
LIST NOT EXHAUSTIVE